Skip to main content
. 2019 Jul 3;8(3):41. doi: 10.3390/antib8030041

Figure 10.

Figure 10

Schematic representation of various CAR formats. Left, natural organization of a CD8+ TCR expressed on cytotoxic T cells driving MHC-restricted CD8+ T cell effects. TCR-CARs are formed by fusing the TCR α/β variable domains to a second-generation CAR scaffold. The Eureka Therapeutics Artemis platform fuses antibody variable domains to TCR α/β constant regions. TCR2 platform fuses scFvs to CD3ε. Triumvira platform fusing two scFv chains to CD8 stalk, hinge and intracellular domains-one scFv binds to CD3ε engaging the rest of the TCR complex, while the second is free to interact with tumor antigens.